A Phase I Study of PU-H71 in Patients with Advanced Cancer

Protocol
11-041
Full Title
The First-in-human Phase I Trial of PU-H71 in Patients with Advanced Malignancies
Phase
I
Purpose

PU-H71 is an investigational drug that works by blocking a protein called Heat Shock Protein 90 (Hsp90). Attacking Hsp90 may stop certain proteins that cancer cells need to survive. In this study, researchers will evaluate PU-H71 for the first time in patients by determining the optimal dose of the drug and observing any side effects in patients with skin cancer, solid tumors, or lymphoma that has returned or progressed despite prior therapy.

On the first day of the study, patients will receive PU-H71 labeled with a small amount of radioactive iodine. This will enable doctors to perform a positron emission tomography (PET) scan to see how the drug is taken up in cancer cells. Patients may also choose to give a tumor tissue sample via needle biopsy so researchers can examine levels of PU-H71 in the tissue.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an incurable, locally advanced, or metastatic solid tumor or lymphoma.
  • At least 4 weeks must have passed since completion of prior therapy and entry into the study.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • Patients must be age 18 or older.

For more information and to inquire about eligibility for this study, please contact Dr. John Gerecitano at 212-639-3748.

Disease(s)
Lymphoma
Locations
Related Diseases

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »